Inspire Medical Systems Reports Strong Growth in 2024

Inspire Medical ( (INSP) ) has released its Q4 earnings. Here is a breakdown of the information Inspire Medical presented to its investors.

Inspire Medical Systems, Inc. is a medical technology company specializing in innovative, minimally invasive solutions for obstructive sleep apnea, known for its proprietary Inspire therapy, the first FDA-approved neurostimulation technology for this condition. Inspire Medical Systems has reported impressive financial results for the fourth quarter and the full year of 2024, with a notable year-over-year revenue growth of 25% and a remarkable 135% increase in earnings per share for the fourth quarter. The company’s revenue reached $239.7 million for the quarter and $802.8 million for the year, with significant operating cash flow and an expanding presence across U.S. medical centers and sales territories. Key financial highlights include a gross margin of 85.0% in Q4, a net income of $35.2 million, and an increase in operating income to $31.9 million. Moreover, the company has successfully activated numerous U.S. centers and increased its sales territories, signaling strong operational growth. Looking ahead, Inspire Medical Systems anticipates continued robust performance in 2025, with projected revenue growth between 17% and 19% and expected diluted earnings per share between $2.10 and $2.20, reflecting management’s positive outlook.